Research
Hormonal
In non-T2DM individuals, retatrutide produced substantial weight loss and improved glucose levels.
Retatrutide may also benefit non-T2DM individuals seeking weight loss and improved glucose control.
StrongSupportsmedium confidence
In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects.
Why this rating
Based on phase-2 trial data mentioned in the abstract.
Source
Retatrutide: a triple incretin receptor agonist for obesity management
Avik Ray · Expert Opinion on Investigational Drugs · 2023
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →